The Pharma & Healthcare industry is of vital importance for human and economic development, providing a wide range of goods and services relevant to the promotion of health at all stages in the healthcare process – from prevention and treatment to rehabilitation and palliative care. It is one of the fastest-growing industries, supported by profound demographic changes, the rising incidence of non-communicable diseases, and surging per capita health spending in both developed and emerging markets. The industry is also one of the major innovators, with increasing expenditures on development of new molecules, biotechnology and adoption of new technologies that provide advanced healthcare and ensure the longevity of the population.
The Pharma & Healthcare industry comprises the manufacture of pharmaceuticals for human and veterinary use, medical equipment and related supplies. It also includes providers of ambulatory health services, medical and diagnostic laboratories, hospitals, and nursing and residential care facilities.
The changing demographic and disease profiles of Hungary were the drivers of the expansion of health expenditure in recent years. As a result, the country spent 7.4% of its GDP on healthcare in 2016, still below the EU average. The government ...View more details
China’s healthcare sector continued to grow in Q4 2018, largely stimulated by the expansion of online healthcare services. The growth was attributed to increasing demand for quality healthcare, driven by the country’s strong economic ...View more details
Turkey’s healthcare system has been fully reformed under the 2003-2013 Health Transformation Programme (HTP), which helped expand the coverage and quality of health services across the country. Health insurance coverage reached 98.4% of the ...View more details
China is the world’s second largest pharmaceutical market after the US and the largest producer and exporter of active pharmaceutical ingredients (APIs) globally. Since it is the world’s most populous country, with a large share of ageing ...View more details
The economy’s return to growth provided a strong impetus to the Russian healthcare sector in 2017. Healthcare expenditure grew by a robust 22% y/y, when measured in US dollar terms, the first increase in many years. However, at USD 92bn in 2017 ...View more details
With 1.4bn population each as of 2017, India and China are the most numerous countries out of the six forming the focus of this report. However, the two countries differ widely in terms of per capita GDP, with that of China being more than twice that ...View more details
Peru is a comparatively small pharmaceutical market in Latin America (ranking eighth in terms of sales volume in 2017), with a relatively young and growing population. However, public health spending is expanding at a rapid pace, particularly in ...View more details
India’s is the world’s 10th-largest pharmaceutical market in US dollar terms - with sales of over USD 25bn in 2017 - and the largest generic drug manufacturer and exporter globally. Strong domestic demand and robust exports have ...View more details
The gross value added (GVA) of the Czech pharmaceutical sector amounted to CZK 19.4bn in 2017, increasing by a real 11.1% y/y. The sector accounted for 0.4% of the GDP that year. The pharmaceutical sector employed 9,855 workers in 2017, accounting ...View more details
Although the global pharma & healthcare sector is dominated by large multinational companies, mainly from the developed countries, Latin America has been quickly catching up in building a domestic pharmaceutical production base and expanding the ...View more details